Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndrome

Blood

Volumn 124, Issue 25, 2014, Pages 3808-3816

  Ripoll, Vera M ^a   Lambrianides, Anastasia ^a,e   Pierangeli, Silvia S ^b   Poulton, Katie ^a   Ioannou, Yiannis ^a   Heywood, Wendy E ^c   Mills, Kevin ^c   Latchman, David S ^d   Isenberg, David A ^a   Rahman, Anisur ^a   Giles, Ian P ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b University of Texas Medical Branch School of Medicine   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF LONDON   (United Kingdom)

^e CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA ACTIN; BETA ACTIN LIKE PROTEIN 3; CAP GLY DOMAIN CONTAINING LINKER PROTEIN 2; CELL PROTEIN; CYTOSKELETON PROTEIN; IMMUNOGLOBULIN G; MESSENGER RNA; MYELOPEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 2; POTE ANKYRIN DOMAIN FAMILY MEMBER E; UNCLASSIFIED DRUG; VIMENTIN; VIMENTIN ANTIBODY; ZINC FINGER CCH DOMAIN CONTAINING PROTEIN 18; ZINC FINGER PROTEIN; PROTEOME;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; CELL ACTIVATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; MALE; MONOCYTE; NUCLEOTIDE SEQUENCE; PREGNANCY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SIGNAL TRANSDUCTION; THROMBOSIS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; U937 CELL LINE; BLOOD; CELL CULTURE; GENETICS; IMMUNOLOGY; LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; PROCEDURES; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

ADULT; ANTIPHOSPHOLIPID SYNDROME; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MONOCYTES; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; U937 CELLS;

EID: 84919681526     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-577569     Document Type: Article

References (36)

1. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum. 1996;39(9):1466-1474.
2. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood. 2007;109(2):422-430.
3. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol. 2004;16(11):1633-1641.
4. López-Pedrera C, Buendía P, Cuadrado MJ, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum. 2006;54(1):301-311.
5. Lambrianides A, Carroll CJ, Pierangeli SS, et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol. 2010;184(12):6622-6628.
6. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
7. Cervera R, Khamashta MA, Shoenfeld Y, et al; Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies). Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009;68(9):1428-1432.
8. Cuadrado MJ, Buendía P, Velasco F, et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost. 2006;4(11):2461-2469.
9. López-Pedrera C, Aguirre MA, Buendía P, et al. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum. 2010;62(3):869-877.
10. López-Pedrera C, Cuadrado MJ, Herández V, et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum. 2008;58(9):2835-2844.
11. López-Pedrera C, Ruiz-Limón P, Aguirre MA, et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis. 2011;70(4):675-682.
12. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277.
13. Giles I, Lambrianides N, Pattni N, et al. Arginine residues are important in determining the binding of human monoclonal antiphospholipid antibodies to clinically relevant antigens. J Immunol. 2006;177(3):1729-1736.
14. Sundström C, Nilsson K. Establishment and characterization of a human histiocytic lymphoma cell line (U-937). Int J Cancer. 1976;17(5):565-577.
15. Heywood WE, Mills P, Grunewald S, et al. A new method for the rapid diagnosis of protein N-linked congenital disorders of glycosylation. J Proteome Res. 2013;12(7):3471-3479.
16. Bennett K, Callard R, Heywood W, et al. New role for LEKTI in skin barrier formation: label-free quantitative proteomic identification of caspase 14 as a novel target for the protease inhibitor LEKTI. J Proteome Res. 2010;9(8):4289-4294.
17. Heywood WE, Madgett TE, Wang D, et al. 2D DIGE analysis of maternal plasma for potential biomarkers of Down syndrome. Proteome Sci. 2011;9:56.
18. Cervera R, Piette JC, Font J, et al; Euro-Phospholipid Project Group. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46(4):1019-1027.
19. Ortona E, Capozzi A, Colasanti T, et al. Vimentin/cardiolipin complex as a new antigenic target of the antiphospholipid syndrome. Blood. 2010;116(16):2960-2967.
20. Moisan E, Girard D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J Leukoc Biol. 2006;79(3):489-498.
21. Boilard E, Bourgoin SG, Bernatchez C, Surette ME. Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2. Blood. 2003;102(8):2901-2909.
22. Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM. Vimentin is secreted by activated macrophages. Nat Cell Biol. 2003;5(1):59-63.
23. Xu B, deWaal RM, Mor-Vaknin N, Hibbard C, Markovitz DM, Kahn ML. The endothelial cellspecific antibody PAL-E identifies a secreted form of vimentin in the blood vasculature. Mol Cell Biol. 2004;24(20):9198-9206.
24. Blaschek MA, Boehme M, Jouquan J, et al. Relation of antivimentin antibodies to anticardiolipin antibodies in systemic lupus erythematosus. Ann Rheum Dis. 1988;47(9):708-716.
25. Mahesh B, Leong HS, McCormack A, Sarathchandra P, Holder A, Rose ML. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol. 2007;170(4):1415-1427.
26. Hamid C, Norgate K, D'Cruz DP, et al. Anti-beta2GPI-antibody-induced endothelial cell gene expression profiling reveals induction of novel proinflammatory genes potentially involved in primary antiphospholipid syndrome. Ann Rheum Dis. 2007;66(8):1000-1007.
27. Medcalf RL, Stasinopoulos SJ. The undecided serpin. The ins and outs of plasminogen activator inhibitor type 2. FEBS J. 2005;272(19):4858-4867.
28. Krone KA, Allen KL, McCrae KR. Impaired fibrinolysis in the antiphospholipid syndrome. Curr Rheumatol Rep. 2010;12(1):53-57.
29. Croucher DR, Saunders DN, Lobov S, Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer. 2008;8(7):535-545.
30. Donato R. S100: a multigenic family of calciummodulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol. 2001;33(7):637-668.
31. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286(17):2136-2142.
32. Telles RW, Ferreira GA, da Silva NP, Sato EI. Increased plasma myeloperoxidase levels in systemic lupus erythematosus. Rheumatol Int. 2010;30(6):779-784.
33. Haraldsson MK, Louis-Dit-Sully CA, Lawson BR, et al. The lupus-related Lmb3 locus contains a disease-suppressing Coronin-1A gene mutation. Immunity. 2008;28(1):40-51.
34. Betapudi V, Lominadze G, Hsi L, Willard B, Wu M, McCrae KR. Anti-b2GPI antibodies stimulate endothelial cell microparticle release via a nonmuscle myosin II motor protein-dependent pathway. Blood. 2013;122(23):3808-3817.
35. Egorina EM, Sovershaev MA, Bjørkøy G, et al. Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability. Arterioscler Thromb Vasc Biol. 2005;25(7):1493-1498.
36. Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med. 1994;96(1):3-9.